Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER-PEDS2 12-month open-label lasmiditan study in pediatric migraine
2023-506724-85-00Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, open-label, single-arm trial of lasmiditan in migraine, sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Treatment Emergent Adverse Events (TEAEs) by treated migraine attack and Percentage of participants with discontinuations due to adverse events. Started Sep 2023; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on 2023-506724-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506724-85-00.